Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Remedy Entertainment Oyj (HEL:REMEDY) due to its excellent fundamentals in more than one area. REMEDY is a company with robust financial health as well as an optimistic future outlook. Below is a brief commentary on these key aspects. If you're interested in understanding beyond my broad commentary, read the full report on Remedy Entertainment Oyj here.
Exceptional growth potential with excellent balance sheet
REMEDY is an attractive stock for growth-seeking investors, with an expected earnings growth of 47% in the upcoming year. Earnings growth is paired with an eye-catching top-line trajectory of 92%, which indicates a high-quality bottom-line expansion, as opposed to those driven simple by unsustainable cost-cutting activities. REMEDY's ability to maintain an adequate level of cash to meet upcoming liabilities is a good sign for its financial health. This implies that REMEDY manages its cash and cost levels well, which is an important determinant of the company’s health. REMEDY's has produced operating cash levels of 0.82x total debt over the past year, which implies that REMEDY's management has put its borrowings into good use by generating enough cash to cover a sufficient portion of borrowings.
For Remedy Entertainment Oyj, I've put together three relevant aspects you should further examine:
- Historical Performance: What has REMEDY's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Valuation: What is REMEDY worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether REMEDY is currently mispriced by the market.
- Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of REMEDY? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.